Correlation Engine 2.0
Clear Search sequence regions


  • alginates (1)
  • baclofen (1)
  • cough (1)
  • diagnosis (1)
  • dysphonia (1)
  • gold (1)
  • h2 receptor (1)
  • help (1)
  • humans (1)
  • larynx (2)
  • patients (2)
  • pharynx (1)
  • proton pump inhibitors (3)
  • reflux (7)
  • reflux gastric (1)
  • therapies (1)
  • throat (2)
  • throat pain (1)
  • Sizes of these terms reflect their relevance to your search.

    Laryngopharyngeal reflux (LPR) is a syndrome caused by reflux of gastric contents into the pharynx or larynx, which leads to symptoms of throat clearing, hoarseness, pain, globus sensation, cough, excess mucus production in the throat, and dysphonia. LPR is a challenging condition, as there is currently no gold standard for diagnosis or treatment, and thus this presents a burden to the healthcare system. Strategies for treatment of LPR are numerous. Medical therapies include proton pump inhibitors, which are first line, H2 receptor antagonists, alginates, and baclofen. Other noninvasive treatment options include lifestyle therapy and the external upper esophageal sphincter compression device. Endoscopic and surgical options include antireflux surgery, magnetic sphincter augmentation, and transoral incisionless fundoplication. Functional laryngeal disorders and laryngeal hypersensitivity can present as LPR symptoms with or without gastroesophageal reflux disease. Though there are minimal studies in this area, neuromodulators and behavioral interventions are potential treatment options. Given the complexity of these patients and numerous available treatment options, we propose a treatment algorithm to help clinicians diagnose and triage patients into an appropriate therapy. © 2021 New York Academy of Sciences.

    Citation

    Amanda J Krause, Erin H Walsh, Philip A Weissbrod, Tiffany H Taft, Rena Yadlapati. An update on current treatment strategies for laryngopharyngeal reflux symptoms. Annals of the New York Academy of Sciences. 2022 Apr;1510(1):5-17

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34921412

    View Full Text